Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Portfolio Pulse from
Medicus Pharma (NASDAQ:MDCX) announced promising interim results from its Phase 2 trial for a non-invasive basal cell carcinoma treatment, with over 60% of patients achieving complete clearance.
March 06, 2025 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicus Pharma's interim results from its Phase 2 trial for a BCC treatment show over 60% complete clearance, indicating strong efficacy and safety, which could positively impact stock prices.
The interim results showing over 60% complete clearance in the Phase 2 trial for BCC treatment suggest strong efficacy and safety, likely boosting investor confidence and positively impacting MDCX stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100